PRMT1

Across TCGA pan-cancer cohorts, PRMT1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRMT1 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRMT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRMT1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

HNSC, PDAC, and COAD are the cancer types where PRMT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.897	1.000	.002	35	view →
PDAC	OS	Tertile	II,III,IV	0.618	0.977	.003	19	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LUAD	DFS	Tertile	II,III,IV	0.991	0.675	.028	4	view →
CCRCC	OS	Median	All	0.729	1.000	.018	2	view →
GBM	OS	Median	All	0.606	0.455	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRMT1–HNSC (DFS)

Open the HNSC breakdown →